Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rapamycin in Relapsed Acute Lymphoblastic Leukemia

This study has been completed.
Brigham and Women's Hospital
Boston Children’s Hospital
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Lewis B. Silverman, M.D., Dana-Farber Cancer Institute Identifier:
First received: April 1, 2009
Last updated: November 21, 2016
Last verified: November 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)